Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 4 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 6 |
| What Defines an OTC Product? | 8 | 1 |
| Why do Companies Switch Rx Products OTC? | 8 | 1 |
| Which OTC Products are Currently Available? | 8 | 2 |
| What Geographical Markets Attract OTC Switching? | 10 | 2 |
| What Are the Potential New Areas For OTC Drug Development and Why? | 12 | 1 |
| GBI Research Report Guidance | 13 | 1 |
| Market Characterization and Forecasts | 14 | 17 |
| Global OTC Market by Revenues | 14 | 1 |
| Global OTC Market by Region | 15 | 1 |
| Global OTC Market - Key Players | 16 | 1 |
| Global OTC Market by Therapy | 17 | 1 |
| The European OTC Market | 18 | 2 |
| France | 20 | 1 |
| Germany | 20 | 1 |
| Italy | 21 | 1 |
| The UK | 21 | 1 |
| Other European Countries | 22 | 1 |
| European OTC Market Forecasts | 23 | 1 |
| Japanese OTC Market | 24 | 1 |
| Japanese OTC Market Forecasts | 25 | 1 |
| North American OTC Market | 26 | 1 |
| The US | 27 | 1 |
| Canada | 28 | 1 |
| Latin American Countries | 28 | 1 |
| North America OTC Market Forecasts | 29 | 1 |
| Trends and Conclusions | 30 | 1 |
| Market Drivers and Restraints | 31 | 1 |
| Growing and Aging Populations | 32 | 13 |
| Emerging Consumer | 34 | 1 |
| Consumer Empowerment and Education | 35 | 1 |
| Unmet Medical Need | 36 | 3 |
| Product Life-Cycle Management | 39 | 2 |
| Patent Expiration | 41 | 1 |
| Healthcare Reform and Government Support | 42 | 1 |
| Advertising | 43 | 1 |
| Trends and Conclusions | 44 | 1 |
| Regulatory Landscape | 45 | 13 |
| Regulation in the US | 45 | 1 |
| OTC New Drug Application (NDA) | 46 | 1 |
| OTC Drug Monograph | 46 | 1 |
| Labeling | 46 | 1 |
| Rx-to-OTC Switches | 47 | 1 |
| Regulations in Europe | 48 | 1 |
| Centralized Route for Drug Approval | 48 | 1 |
| Decentralized Procedure for drug approval | 49 | 1 |
| National Procedure for Drug Approval | 50 | 2 |
| Drug Classification in Europe | 52 | 1 |
| EU Harmonization | 53 | 1 |
| Regulations in Japan | 54 | 3 |
| Trends &Conclusions | 57 | 1 |
| Therapy Areas | 58 | 14 |
| Coughs, Colds and Allergies | 59 | 1 |
| Case Study: Claritin (Merck) | 60 | 2 |
| Case Study: Sudafed (J&J) | 62 | 1 |
| Case Study: Allegra (Sanofi) | 62 | 1 |
| OTC Respiratory Conclusions | 62 | 1 |
| Analgesics and Pain Management | 63 | 1 |
| Case Study: Nurofen (Reckitt Benckiser) | 64 | 1 |
| Case Study: Advil (Pfizer/Wyeth) | 65 | 1 |
| Case Study: Tylenol (McNeil/J&J) | 66 | 1 |
| OTC Pain Conclusions | 66 | 1 |
| Gastrointestinal Remedies and Indigestion | 67 | 1 |
| Case Study: Zantac (GlaxoSmithKline/Warner-Lambert) | 68 | 1 |
| Prilosec OTC (Proctor &Gamble/AstraZeneca) | 69 | 1 |
| Pantazol/Pantazol Control (Nycomed) | 69 | 1 |
| Gastrointestinal OTC Conclusions | 70 | 1 |
| Medicated Dermatological Products | 70 | 1 |
| Case Study: Lamisil (Novartis) | 71 | 1 |
| Trends and Conclusions | 71 | 1 |
| Company Analysis | 72 | 24 |
| Johnson &Johnson | 73 | 1 |
| OTC M&A activity | 74 | 1 |
| OTC Production Issues | 74 | 1 |
| GlaxoSmithKline | 75 | 3 |
| OTC Divestment | 78 | 1 |
| Reckitt Benckiser | 79 | 1 |
| OTC M&A Activity | 80 | 1 |
| Bayer Healthcare AG | 81 | 1 |
| Restructuring | 82 | 1 |
| Product Line Extensions | 82 | 1 |
| Expansion in Fast-Growing Regions | 83 | 1 |
| Procter &Gamble | 83 | 2 |
| Joint Venture | 85 | 1 |
| Novartis | 85 | 3 |
| Sanofi | 88 | 1 |
| New Product Launches | 89 | 1 |
| Boehringer Ingelheim GmbH | 90 | 2 |
| Merck &Co. | 92 | 2 |
| Pfizer | 94 | 1 |
| Trends &conclusions | 95 | 1 |
| Challenges and Opportunities in the OTC Market | 96 | 6 |
| Business Strategies | 96 | 1 |
| Model for Rx-to-OTC switching | 96 | 2 |
| Brand identity and private labeling | 98 | 1 |
| Behind-the-Counter Opportunities | 99 | 1 |
| Opportunities in the emerging markets | 100 | 1 |
| Outlook | 100 | 2 |
| Appendix | 102 | 6 |
| Key Definitions | 102 | 1 |
| Abbreviations (in alphabetical order) | 102 | 1 |
| Sources | 103 | 2 |
| Methodology | 105 | 3 |
| Primary Research | 106 | 1 |
| Secondary Research | 106 | 1 |
| Contacts Us | 106 | 1 |
| Disclaimer | 107 | 1 |